RTC 1119
Alternative Names: RTC-1119Latest Information Update: 30 May 2024
At a glance
- Originator Ripple Therapeutics
- Class Antiglaucomas; Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Ocular hypertension; Open-angle glaucoma
Most Recent Events
- 30 May 2024 Preclinical trials in Ocular hypertension in Canada (Intraocular) (Ripple Therapeutics pipeline, May 2024)
- 30 May 2024 Preclinical trials in Ocular hypertension in Canada (Intravitreous) (Ripple Therapeutics pipeline, May 2024)
- 30 May 2024 Preclinical trials in Open-angle glaucoma in Canada (Intravitreous) (Ripple Therapeutics pipeline, May 2024)